AU2020291012B2 - Novel IL-15 prodrugs and methods of use thereof - Google Patents

Novel IL-15 prodrugs and methods of use thereof

Info

Publication number
AU2020291012B2
AU2020291012B2 AU2020291012A AU2020291012A AU2020291012B2 AU 2020291012 B2 AU2020291012 B2 AU 2020291012B2 AU 2020291012 A AU2020291012 A AU 2020291012A AU 2020291012 A AU2020291012 A AU 2020291012A AU 2020291012 B2 AU2020291012 B2 AU 2020291012B2
Authority
AU
Australia
Prior art keywords
seq
moiety
antibody
prodrug
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020291012A
Other languages
English (en)
Other versions
AU2020291012A1 (en
Inventor
Jian-Feng Lu
Yuefeng Lu
Chunxiao YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askgene Pharma Inc
Original Assignee
Askgene Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askgene Pharma Inc filed Critical Askgene Pharma Inc
Publication of AU2020291012A1 publication Critical patent/AU2020291012A1/en
Application granted granted Critical
Publication of AU2020291012B2 publication Critical patent/AU2020291012B2/en
Priority to AU2025283612A priority Critical patent/AU2025283612A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020291012A 2019-06-12 2020-06-12 Novel IL-15 prodrugs and methods of use thereof Active AU2020291012B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025283612A AU2025283612A1 (en) 2019-06-12 2025-12-19 Novel IL-15 prodrugs and methods of use thereof

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962860635P 2019-06-12 2019-06-12
US62/860,635 2019-06-12
US201962888444P 2019-08-17 2019-08-17
US62/888,444 2019-08-17
US201962891190P 2019-08-23 2019-08-23
US62/891,190 2019-08-23
US202062959973P 2020-01-11 2020-01-11
US62/959,973 2020-01-11
US202063029473P 2020-05-23 2020-05-23
US63/029,473 2020-05-23
PCT/US2020/037439 WO2020252264A1 (en) 2019-06-12 2020-06-12 Novel il-15 prodrugs and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025283612A Division AU2025283612A1 (en) 2019-06-12 2025-12-19 Novel IL-15 prodrugs and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2020291012A1 AU2020291012A1 (en) 2021-12-16
AU2020291012B2 true AU2020291012B2 (en) 2025-09-25

Family

ID=71995031

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020291012A Active AU2020291012B2 (en) 2019-06-12 2020-06-12 Novel IL-15 prodrugs and methods of use thereof
AU2025283612A Pending AU2025283612A1 (en) 2019-06-12 2025-12-19 Novel IL-15 prodrugs and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025283612A Pending AU2025283612A1 (en) 2019-06-12 2025-12-19 Novel IL-15 prodrugs and methods of use thereof

Country Status (8)

Country Link
US (2) US11845801B2 (enExample)
EP (1) EP3983432A1 (enExample)
JP (1) JP7676329B2 (enExample)
KR (1) KR102962557B1 (enExample)
CN (1) CN114341189A (enExample)
AU (2) AU2020291012B2 (enExample)
CA (1) CA3141626A1 (enExample)
WO (1) WO2020252264A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
PH12022552630A1 (en) * 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CA3179066A1 (en) * 2020-05-18 2021-11-25 Jing DENG Human il-15 mutant and use thereof
KR20230104866A (ko) * 2020-09-16 2023-07-11 베이진 엘티디 인터류킨 15 작제물 및 사용 방법
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
EP4284819A1 (en) * 2021-02-01 2023-12-06 Askgene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
IL304916A (en) * 2021-02-05 2023-10-01 Salubris Biotherapeutics Inc Il-15 fusion proteins and methods of making and using same
KR20230157448A (ko) * 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
WO2023280307A1 (en) * 2021-07-09 2023-01-12 Nanjing Legend Biotech Co., Ltd. Mutant il-15 compositions and methods thereof
WO2023280287A1 (en) * 2021-07-09 2023-01-12 Nanjing Legend Biotech Co., Ltd. Interleukin-15 variants and uses thereof
EP4376869A1 (en) * 2021-07-28 2024-06-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
EP4376870A4 (en) * 2021-07-28 2025-07-23 Anwita Biosciences Inc INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
CN117088975B (zh) * 2022-05-11 2024-06-25 东莞市朋志生物科技有限公司 抗白蛋白抗体、检测白蛋白的试剂和试剂盒
WO2024039973A2 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, activatable novel prodrugs and methods of use thereof
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
CN120112312A (zh) * 2022-10-18 2025-06-06 Tubulis 股份有限公司 新型抗-tpbg抗体和基于其的抗体-药物偶联物、其治疗方法及用途
WO2024137136A1 (en) * 2022-12-22 2024-06-27 University Of Houston System Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025180355A1 (zh) * 2024-02-27 2025-09-04 江苏奥赛康生物医药有限公司 Il-15前药与免疫检查点抑制剂的组合
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
DE10045592A1 (de) 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
GB0100551D0 (en) 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
KR100911951B1 (ko) 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (ｉｌ-15)에 대하여 특이적인 인간 항체
EP3254687A1 (en) 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
NZ567242A (en) 2001-10-04 2009-11-27 Genetics Inst Llc Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
KR20050049545A (ko) 2002-10-14 2005-05-25 에프. 호프만-라 로슈 아게 길항제 ｉｌ-15
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CN1921879A (zh) 2003-12-29 2007-02-28 明斯特大学临床医学院 由il－15刺激和活化毛发生长的方法
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
EP2109620B1 (en) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
WO2012061536A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3093295B1 (en) 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016090173A1 (en) 2014-12-03 2016-06-09 Rxi Pharmaceuticals Corporation Methods for the treatment of alopecia areata utilizing gene modulation approaches
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
US20160362469A1 (en) 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
US10858452B2 (en) 2015-09-16 2020-12-08 Insitut National de la Sante et de la Recherche Medicale (INSERM) Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
HRP20250482T1 (hr) 2016-12-21 2025-06-20 Cephalon Llc Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
JP2020528878A (ja) 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
JP7778571B2 (ja) 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US20240076355A1 (en) 2021-01-14 2024-03-07 AskGene Pharma, Inc. Interferon Prodrugs and Methods of Making and Using the Same
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
EP4284819A1 (en) 2021-02-01 2023-12-06 Askgene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
WO2022178103A1 (en) 2021-02-17 2022-08-25 AskGene Pharma, Inc. Il-2 receptor beta subunit mutants
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Also Published As

Publication number Publication date
KR20220020879A (ko) 2022-02-21
JP7676329B2 (ja) 2025-05-14
CA3141626A1 (en) 2020-12-17
AU2025283612A1 (en) 2026-01-22
WO2020252264A1 (en) 2020-12-17
US20200392235A1 (en) 2020-12-17
US20240067739A1 (en) 2024-02-29
US11845801B2 (en) 2023-12-19
KR102962557B1 (ko) 2026-05-08
CN114341189A (zh) 2022-04-12
EP3983432A1 (en) 2022-04-20
AU2020291012A1 (en) 2021-12-16
JP2022536898A (ja) 2022-08-22

Similar Documents

Publication Publication Date Title
US20240067739A1 (en) Novel il-15 prodrugs and methods of use thereof
US20250127858A1 (en) Novel cytokine prodrugs
US12459980B2 (en) IL-21 prodrugs and methods of use thereof
US12600762B2 (en) Masked cytokines and methods of use thereof
CN114401997B (zh) 细胞因子前药和双前药
US20220289822A1 (en) Novel il-21 prodrugs and methods of use thereof
CN108650886B (zh) 多价和多特异性gitr-结合融合蛋白
EP4406965A1 (en) Interleukin-2 mutant and fusion protein thereof
JP2022512653A (ja) Ｐｄ－１単一ドメイン抗体およびその治療用組成物
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
US20240076355A1 (en) Interferon Prodrugs and Methods of Making and Using the Same
WO2022178103A1 (en) Il-2 receptor beta subunit mutants
AU2023403270A1 (en) Mutant il-2 polypeptides and il-2 prodrugs
AU2023412611A1 (en) Novel anti-gprc5d antibody
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
WO2022187710A1 (en) Epha2 antibodies
WO2025122660A1 (en) Chimeric proteins comprising masked il-2
US11773160B1 (en) Immune-stimulating IL-2 fusion proteins
WO2025064951A1 (en) Anti-tumor antibodies
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)